Highlights

  • LTR Pharma (ASX:LTP) received ethics approval to begin its first-in-human OROFLOW clinical study.
  • OROFLOW is an intranasal spray being developed for oesophageal motility disorders.
  • The PILOT study will evaluate safety, tolerability and effects on oesophageal function.
  • The program expands LTR Pharma’s nasal delivery platform beyond erectile dysfunction treatments.

LTR Pharma (ASX:LTP) has progressed its intranasal drug-delivery platform into a new therapeutic area after receiving ethics approval for the OROFLOW clinical study.

The approval allows the company to begin human testing of an experimental nasal spray designed for oesophageal motility disorders, extending its platform beyond its existing erectile dysfunction programs.

The study remains an early-stage clinical investigation, with future value dependent on human data and subsequent development progress.

What Happened?

On 24 June 2026, LTR Pharma announced that the South Eastern Sydney Local Health District Human Research Ethics Committee had approved the PILOT study for OROFLOW.

The investigator-initiated study will evaluate OROFLOW in oesophageal motility disorders, with Dr Peter Wu, Director of St George Motility Services, appointed as principal investigator.

OROFLOW uses LTR Pharma’s intranasal delivery technology and applies a PDE5-inhibitor approach designed to improve smooth muscle function in the oesophagus.

The ethics approval allows the company to begin recruiting participants for the study.

Why It Matters

The approval provides the first opportunity to evaluate whether LTR Pharma’s nasal delivery technology can be applied beyond erectile dysfunction.

Oesophageal motility disorders affect the ability of the muscles involved in swallowing to move food and liquid effectively. For patients with swallowing difficulties, a nasal delivery format may provide an alternative administration route.

The program also expands LTR Pharma’s development pipeline, reducing reliance on a single therapeutic area.

However, OROFLOW remains an exploratory clinical program and is intended to generate early human data rather than support immediate commercialisation.

The Numbers

The PILOT study will be conducted in two stages.

The first stage will evaluate OROFLOW in healthy volunteers, followed by assessment in patients with oesophageal motility disorders.

The study will measure outcomes including oesophageal contractility, bolus flow timing and bolus distension pressure.

The target conditions include achalasia, oesophageal outflow obstruction, diffuse oesophageal spasm and hypercontractility.

LTR Pharma has referenced external market estimates valuing the global oesophageal motility disorder treatment market at approximately US$4.5 billion in 2024, with projections reaching US$8.1 billion by 2034.

The company has also highlighted that its erectile dysfunction products have demonstrated onset of action within 10 minutes or less, although performance in one indication does not confirm outcomes in another.

The Bigger Picture

OROFLOW represents an expansion of LTR Pharma’s broader intranasal delivery strategy.

The company’s leading programs include SPONTAN, an intranasal erectile dysfunction treatment, and ROXUS, an erectile dysfunction product being developed for the US market.

SPONTAN has progressed through clinical development planning, while ROXUS forms part of LTR Pharma’s commercial strategy.

OROFLOW was developed through a co-development arrangement with Strategic Drug Solutions and applies the same delivery technology framework.

The company’s strategy is based on using its nasal platform across multiple therapeutic areas, although each indication requires separate clinical validation.

The Bull Case

The positive case for LTR Pharma (ASX:LTP) is based on expanding its intranasal delivery platform into additional medical applications.

OROFLOW provides an opportunity to demonstrate that the company’s technology can address conditions where swallowing tablets may present challenges.

A successful human study could support further development and increase confidence in the broader platform approach.

The company’s existing erectile dysfunction programs may also provide supporting experience in Manufacturing and commercial development.

Risks Investors Should Understand

LTR Pharma (ASX:LTP)’s Business faces risks including clinical trial uncertainty, regulatory requirements, funding needs and limited validation of OROFLOW.

First-in-human studies may not reproduce results observed in preclinical or related applications.

The PILOT study is exploratory, and positive results would require confirmation through larger controlled studies before regulatory approval pathways become clear.

Success in erectile dysfunction treatments does not guarantee effectiveness in oesophageal motility disorders.

Advancing multiple clinical programs may require additional funding, and timelines could be affected by recruitment, development or regulatory delays.

What Comes Next?

The next milestone is commencement and completion of the OROFLOW PILOT study.

Investors will monitor initial human safety and functional data, followed by any decision regarding larger clinical studies.

Progress in SPONTAN clinical development and ROXUS commercial activities will also remain important, as these programs represent nearer-term commercial opportunities.

Conclusion

LTR Pharma (ASX:LTP) has advanced OROFLOW from a development concept into a clinical program following ethics approval for its first-in-human study.

The milestone provides an opportunity to test whether the company’s intranasal delivery technology can be applied to oesophageal motility disorders.

However, OROFLOW remains an early-stage program, and its future depends on clinical results, regulatory progress and commercial execution. The upcoming PILOT study will provide the first human evidence of whether the platform can expand beyond its original therapeutic focus.